Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

PD-1/PD-L1 blocking therapy has become one of the most promising methods in the field of tumor treatment. However, it encounters the challenge of immune escape due to the exhaustion of T cells. Studies have shown that the epigenetic regulation drug histone deacetylase inhibitor (HDACi) may be able t...

Full description

Bibliographic Details
Main Authors: Fengkun Lu, Lei Hou, Sizhen Wang, Yingjie Yu, Yunchang Zhang, Linhong Sun, Chen Wang, Zhiqiang Ma, Feng Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Drug Delivery
Subjects:
histone deacetylase inhibitor (hdaci)
hdaci prodrug
immunotherapy
sirna-pd-l1
pd-l1kd
Online Access:http://dx.doi.org/10.1080/10717544.2021.1927246

Internet

http://dx.doi.org/10.1080/10717544.2021.1927246

Similar Items